December 20 2023

Indivior Settles Patent Dispute with Teva Subsidiary Actavis

December 5 2023

Indivior Prevails in Striking Representative Claims from UK Shareholder Action

November 9 2023

Indivior Announces Q3 2023 Financial Results

October 23 2023

Indivior Reaches Agreement with Direct Purchasers to Resolve Antitrust Multi-District Litigation; Provides Preliminary Q3 and YTD 2023 Results

October 11 2023

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

August 21 2023

Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims

July 27 2023

Indivior Announces H1 and Q2 2023 Financial Results

June 14 2023

Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence

June 12 2023

Indivior to Commence Trading on Nasdaq

June 2 2023

Indivior Reaches Agreement with States’ Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims

May 23 2023

Trading on NASDAQ Expected to Commence on June 12th

May 22 2023

Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

April 27 2023

Indivior Announces Q1 2023 Financial Results

April 25 2023

Indivior to Participate in Bank of America Global Healthcare Conference 2023

March 2 2023

Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc.

February 16 2023

Indivior Announces FY 2022 Financial Results

January 20 2023

Indivior to Announce Q4 / FY 2022 Results and Host Webcast on February 16th

December 7 2022

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth Outlook

November 14 2022

Indivior to Acquire Opiant Pharmaceuticals

October 27 2022

Indivior Announces Q3 2022 Financial Results

October 5 2022

Indivior to Announce Q3 / 9 Months YTD 2022 Results and Host Webcast on October 27th

September 30 2022

Indivior Shareholders Approve Resolutions to Proceed with Additional U.S. Listing

September 6 2022

Indivior To Participate in Upcoming Investor Healthcare Events

September 5 2022

Indivior PLC (the 'Company') Publication of Circular and Notice of General Meeting

September 1 2022

Indivior Recognizes National Recovery Month, Commits to Helping Move People living with Opioid Use Disorder onto a Path to Hope and Recovery

August 25 2022

Indivior Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S.

July 28 2022

Indivior Announces H1 and Q2 2022 Financial Results

July 7 2022

Indivior to Announce Q2/H1 2022 Results and Host Webcast on July 28th

June 16 2022

Indivior Names Nina DeLorenzo Chief Global Impact Officer

June 8 2022

Indivior Announces Seven Abstracts Accepted for Presentation at the 84th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD)

June 1 2022

Indivior Announces First Patient Included in Aelis Farma’s Phase 2b Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects With Moderate to Severe Cannabis Use Disorder

May 26 2022

Indivior Announces Publication of Data Showing Psychosocial Benefits from a 4-year Post-Clinical Trial Outcomes Study

May 26 2022

Indivior to Participate in Jefferies 2022 Healthcare Conference

May 19 2022

For Mental Health Awareness Month, Indivior Offers Hope for Opioid Use Disorder Recovery Through One Man’s Inspiring Story

May 10 2022

Indivior Lends Voice to Help Raise Awareness of Substance Use Disorder During Mental Health Awareness Month and National Fentanyl Awareness Day

April 28 2022

Indivior Announces Q1 2022 Financial Results

April 28 2022

Indivior Statement on the Biden Administration’s National Drug Control Strategy

April 27 2022

The Board of Indivior PLC today announces the appointment of Barbara Ryan as an Independent Non-Executive Director

April 11 2022

Indivior Statement on Nationwide Increases in Fentanyl-Related Mass-Overdose Events

April 8 2022

Indivior Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users

April 7 2022

Indivior to Announce Q1 2022 Results and Host Webcast on April 28th

April 1 2022

Indivior Presents New Integrated Analysis Evaluating Long-Term Benefits of SUBLOCADE® (buprenorphine-extended release) Injection

March 31 2022

Indivior to Commence Formal Shareholder Consultations on Additional US Listing

March 1 2022

National Commission on Correctional Health Care Foundation Publication Highlights the Critical Role of Medications for Opioid Use Disorder (MOUD) for Opioid Dependent Individuals in the Criminal Justice System

February 16 2022

Indivior Announces Q4 / FY 2021 Financial Results

February 1 2022

Indivior to Announce FY 2021 Results and Host a Presentation on February 16th

January 27 2022

Research Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant Participants

December 8 2021

Indivior to Present New Data on Buprenorphine Extended-Release at the 2021 Joint International Congress with ALBATROS and the World Association on Dual Disorder (WADD)

November 8 2021

Indivior Presents Modelling Data on Interaction Between Buprenorphine and Fentanyl in Opioid-Naïve and Opioid-Tolerant Subjects at the 2021 American Conference of Pharmacometrics

November 2 2021

Indivior to Participate in Upcoming November 2021 Healthcare Investor Conferences

November 1 2021

Indivior Presents Study at the 2021 National Commission on Correctional Health Care Conference on Factors Impacting Medications for Opioid Use Disorder Treatment Approaches in Criminal Justice-Involved Populations

October 28 2021

Indivior Announces Q3 and Nine Months 2021 Results; Raises FY 2021 Guidance

October 27 2021

Indivior Applauds New York State Legislation to Combat Opioid Crisis for People Suffering from Substance Use Disorder within the New York State and Local Correctional institutions

October 21 2021

Indivior to Present New Data on Opioid Use Disorder at CSAM-SMCA 2021 Scientific Conference

September 14 2021

Indivior to Participate in Upcoming Healthcare Events During National Recovery Month

September 9 2021

Indivior to Participate in Upcoming Investor Conferences

July 27 2021

Indivior Announces H1 and Q2 2021 Financial Results

July 21 2021

Indivior to Announce Q2/H1 2021 Results and Host a Presentation on July 29th

June 30 2021

Indivior Raises FY 2021 Guidance

June 24 2021

Indivior Presents New Data at the College on Problems of Drug Dependence (CPDD) 2021 Annual Conference

June 8 2021

Indivior Extends Leadership Position in Substance Use Disorder Treatment with Exclusive Agreement for Leading Asset Targeting Cannabis-Related Disorders.

April 30 2021

Indivior Applauds Biden Administration’s New Buprenorphine Practice Guidelines

April 29 2021

Indivior Announces Q1 2021 Financial Results

April 28 2021

Indivior Statement Regarding State Attorney General’s Recent Announcements Relating to SUBOXONE® (buprenorphine and naloxone) Film Settlements

April 22 2021

Indivior Welcomes White House Announcement Prioritizing Expanded Access to Evidence-Based Treatment

April 22 2021

Study Examining Impact of COVID-19 Pandemic on Opioid Use Disorder (OUD) Finds Greater Barriers to Care During Pandemic

March 24 2021

Board Appointments and Succession Plan Announced

March 22 2021

Indivior Recognizes Drug and Alcohol Facts Week® 2021

February 18 2021

Indivior Announces FY 2020 Financial Results

February 18 2021

Indivior FY 2020 Financial Results Presentation

January 25 2021

Indivior Reaches Settlement with Reckitt Benckiser

January 15 2021

Indivior Provides Preliminary FY 2020 Financial Results Ahead of Guidance

January 15 2021

The Department of Health and Human Services Announces New Guidance Intended to Expand Access to Medication-Assisted Treatment for the Treatment of Opioid Use Disorder

January 12 2021

Indivior PLC – Directorate Change

November 30 2020

Indivior Statement related to a claim filed against it by Reckitt Benckiser Group

November 27 2020

Claim filed by Reckitt Benckiser Group plc

November 20 2020

Appointment of Chief Financial Officer

November 19 2020

Appointment of Non-Executive Chair

November 13 2020

US Court Approval of Agreement with Justice Department

October 29 2020

Indivior Announces 2020 Nine Months Financial Results

October 23 2020

US Court Sentencing of Former CEO

September 30 2020

Indivior Calls for Widespread Commitment to Tackling Stigma in Patients with Opioid Use Disorder

September 24 2020

Indivior Takes Strategic Alignment Actions

September 22 2020

Indivior Underscores Commitment to Putting Patients First during this Recovery Month

September 8 2020

Indivior PLC - Board Announcement

September 4 2020

Motion to Expedite DRL’s Appeal of Indivior’s Preliminary Injunction Granted-in-Part

July 30 2020

Indivior Announces First Half and Second Quarter 2020 Results

July 24 2020

An Open Letter to our Stakeholders from our Interim Board Chair and CEO regarding Indivior Agreement

July 24 2020

Indivior Announces Agreement to Resolve Criminal Charges and Civil Complaints Related to SUBOXONE® Film

June 30 2020

US Government Agreement with Former CEO

June 29 2020

Appointment of Chief Executive Officer

June 24 2020

New Data from the RECOVER™ Study Reveal Two-Year Outcomes in People with Opioid Use Disorder Following Transition from Pivotal Phase 3 Clinical Trials to a Real-World Setting

June 3 2020

Indivior Announces Patent Trial and Appeal Board Ruling in Dr. Reddy’s Laboratories (DRL)’s Petition for Inter Partes Review of U.S. Patent No. 9,687,454 (the ‘454 Patent)

May 14 2020

Q1 2020 Indivior Financial Results Press Release

May 6 2020

Indivior receives approval for SUBUTEX® prolonged release solution for injection, 100mg and 300mg for substitution treatment of opioid dependence in Sweden

April 27 2020

Directorate Change

April 20 2020

Indivior to Announce Q1 2020 Results - May 14th

April 16 2020

SUBLOCADE® Long-Term Safety Data Published in Journal of Clinical Psychopharmacology

April 8 2020

Indivior Withdraws FY 2020 Guidance in Face of Current COVID-19 Uncertainty

March 23 2020

Statement on the Coronavirus and Global Supply of Medicines

March 23 2020

One-Year Outcomes of Real-World RECOVER™ Study Published in Journal of Addiction Medicine

March 13 2020

Annual Report & Accounts 2019 and Annual General Meeting 2020

February 13 2020

Indivior Announces FY 2019 Financial Results

February 10 2020

Indivior to Announce and Present FY 2019 Results on February 13th

February 5 2020

The White House Office of National Drug Control Policy: National Drug Control Strategy and National Treatment Plan for Substance Use Disorder Addresses the ‘Treatment Gap'

December 10 2019

Virginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder

December 2 2019

New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes

November 11 2019

Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can “Keep Moving Towards Recovery”

October 31 2019

Indivior Announces 2019 Third Quarter and Nine Months YTD Results

October 15 2019

Indivior Raises FY 2019 Net Revenue and Net Income Guidance

September 26 2019

Announcement of National Institutes of Health (NIH) Grant Award through the NIH Helping to End Addiction Long-term (HEAL) Initiative

July 31 2019

Indivior Directorate Changes

July 31 2019

Indivior Announces H1 2019 Financial Results

July 29 2019

Indivior PLC – Director’s Change of Responsibilities

July 15 2019

Indivior Announces Ruling by the Court of Appeals for the Federal Circuit in ANDA Litigation

July 11 2019

Indivior Statement Regarding Reckitt Benckiser Settlement

July 11 2019

Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m

June 18 2019

Indivior Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for SUBOXONE® (buprenorphine and naloxone) Sublingual Film

June 17 2019

New Data from the RECOVER™ Study Reports on Abstinence, Drug Craving and Psychosocial Outcomes in People with Opioid Use Disorder following Transition from a Clinical Trial to the Real-World Setting

May 16 2019

Indivior to Participate in Jefferies 2019 Healthcare Conference

May 9 2019

Indivior Enters into Exclusive License Agreement with HLS Therapeutics for PERSERIS™ (risperidone) in Canada

May 2 2019

Indivior PLC Q1 2019 Financial Results

April 9 2019

Company Believes U.S. Justice Department Is Fundamentally Wrong, Will Contest Charges Vigorously

April 8 2019

Indivior Announces New Study Data in Patients with Moderate to Severe Opioid Use Disorder (OUD) at the 50th ASAM Annual Conference

April 5 2019

Indivior’s RECOVER™ Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE™ (Buprenorphine Extended-Release) Injection were Abstinent from Illicit Opioids One Year Later

March 7 2019

The Journal of Addiction Medicine Publishes Patient-centered Outcomes from the Phase 3 Study of SUBLOCADE™ (Buprenorphine Extended-Release) Injection in Patients with Moderate to Severe Opioid Use Disorder (OUD)

February 27 2019

Indivior Announces Launch of PERSERIS™ (risperidone) for the Treatment of Schizophrenia in Adults

February 20 2019

Indivior Announces Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film Authorized Generic

February 19 2019

The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety and Tolerability of SUBLOCADE™ (Buprenorphine Extended-Release) Injection for Subcutaneous Use (CIII) in Patients with Moderate to Severe Opioid Use Disorder (OUD)

February 14 2019

Indivior PLC FY 2018 Financial Results

February 12 2019

Court of Appeals for the Federal Circuit Denies Motion to Stay Issuance of the Mandate

February 5 2019

Court of Appeals for the Federal Circuit (CAFC) Denies Motion for Rehearing or Rehearing En Banc Following the CAFC’s Ruling Vacating the Preliminary Injunction Granted against Dr. Reddy’s Laboratories

February 4 2019

Indivior to Divest Interest in China

February 4 2019

Indivior Enters into Agreement with Alvogen on Generic (buprenorphine and naloxone) Sublingual Film

January 25 2019

Indivior Is Granted Temporary Restraining Order on Generic (buprenorphine and naloxone) Sublingual Film

January 21 2019

Indivior to Announce FY 2018 Results on February 14th

December 20 2018

Indivior Publishes Design and Patient Characteristics for Real-World Study of Life Changes in People Treated with SUBLOCADE™ (Buprenorphine Extended-Release) in Contemporary Clinical Trials

December 18 2018

Trading Update Release

December 12 2018

Court of Appeals for the Federal Circuit Declines to Immediately Issue Mandate After Preliminary Injunction Ruling

November 30 2018

Indivior Prepays Debt

November 23 2018

Indivior Announces Health Canada Approval of SUBLOCADE™ (Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder

November 21 2018

Court of Appeals for the Federal Circuit Lifts Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film

November 20 2018

Indivior Statement on Court Decision

November 19 2018

PERSERIS™, the First Once-Monthly Risperidone-Containing Subcutaneous Long-Acting Injectable, Now Available in the U.S. for the Treatment of Schizophrenia in Adults

November 6 2018

Indivior Announces Upcoming Investor Events

November 1 2018

Indivior Q3 2018 Financial Results

October 24 2018

SUPPORT for Patients and Communities Act of 2018

October 19 2018

Third Quarter Results Notification & Call Information

September 26 2018

Indivior Provides Update on Key Business Drivers and Expectations

September 12 2018

Indivior unable to attend Investor Conference

September 10 2018

Indivior Prepays $150 Million of Outstanding Debt

September 4 2018

Morgan Stanley Annual Global Healthcare Conference

August 21 2018

Holding(s) in Company 08/21/2018

August 10 2018

Holding(s) in Company 8/10/2018

August 6 2018

Holding(s) in Company 8/6/2018

July 31 2018

Indivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld

July 27 2018

FDA Approves PERSERIS™ (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults

July 25 2018

Indivior H1 2018 Financial Results

July 10 2018

Indivior to Announce and Present Half Year 2018 Results on July 25th

July 7 2018

Indivior Sees FY 2018 Net Revenue and Adjusted Net Income Below Previous Expectations

June 15 2018

Indivior Is Granted Temporary Restraining Order

June 15 2018

Indivior Responds to Generic SUBOXONE® Approvals and Dr. Reddy’s Launch “At-Risk”

May 31 2018

Indivior Receives Subpoena from California Department of Insurance

May 25 2018

Indivior Announces Regulatory Submission to Australia’s Therapeutic Goods Administration (TGA) for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence

May 17 2018

Result of AGM

May 14 2018

Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case

May 1 2018

Indivior Q1 2018 Results On Track. FY 2018 Guidance Reconfirmed. Encouraging SUBLOCADE™ Launch.

April 20 2018

April 13 2018

Patient-Reported Outcomes Data on SUBLOCADEᵀᴹ (Buprenorphine Extended-Release) Injection to be Presented as Late-Breaker at American Society of Addiction Medicine (ASAM) 49ᵗʰ Annual Conference

April 11 2018

Indivior to Announce First Quarter 2018 Results on May 2nd and Host Conference Call

April 5 2018

Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers

March 29 2018

Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery’s Orexin-1 (OX1) Antagonist Program

March 23 2018

Indivior Responds To Court Ruling In ANDA Litigation And Announces Intention To Appeal

March 22 2018

Annual Report & Accounts 2017 and Annual General Meeting 2018

March 1 2018

SUBLOCADE™ (Buprenorphine Extended-Release) is Now Available as First and Only Monthly Injectable Buprenorphine in the U.S. to Treat Patients with Moderate to Severe Opioid Use Disorder

February 15 2018

Indivior PLC Full Year 2017 Financial Results

February 12 2018

Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers

February 6 2018

Indivior to Announce Full Year 2017 Results on February 15th

February 1 2018

January 11 2018

JP Morgan Healthcare Conference Presentation – Strengthening Our Global Leadership in Treatment of Addiction

January 3 2018

Indivior and Addex Enter Strategic Collaboration to Accelerate Development of GABAB PAMs for Addiction Disorder Treatments

December 19 2017

Indivior Announces Repricing and Maturity Extension of Term Loan Facilities and Replacement of Credit Facility

December 12 2017

Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot

November 30 2017

FDA Approves SUBLOCADE™ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder

November 2 2017

Q3 / YTD 2017 Financial Results

October 31 2017

FDA Advisory Committees Recommend Approval of Indivior’s RBP-6000 for the Treatment of Opioid Use Disorder

October 3 2017

FDA Posts Advisory Committee Meeting Notice for RBP-6000 NDA

October 2 2017

Indivior Submits New Drug Application to U.S. FDA for RBP-7000 Risperidone Monthly Depot for Treatment of Schizophrenia

September 27 2017

Indivior Chief Medical Officer Ponni Subbiah, M.D., Provides Testimony Before the Presidential Commission on Combating Drug Addiction and the Opioid Crisis

September 25 2017

Indivior Enters into Settlement with Mylan Pharmaceuticals in Patent Infringement Case

September 2 2017

Indivior Asserts New Patent Against ANDA Filers

September 1 2017

Indivior Responds To Court Rulings in ANDA Litigation and Announces Intention To Appeal

August 22 2017

Indivior Opens $30 Million Research and Development Center to Advance Treatment Innovation

July 31 2017

Indivior RBP-6000 NDA Acceptance with Priority Review Designation

July 31 2017

Indivior’s NALSCUE® Receives Marketing Authorization from French Regulatory Agency ANSM

July 27 2017

Indivior H1 2017 Financial Results

July 13 2017

Indivior to Announce Half Year 2017 Results on July 27th

June 29 2017

Reminder RBP-6000 Investor Event Announcement

June 21 2017

RBP-6000 Data Presented in Late-Breaking Research Oral Session at CPDD 79th Annual Scientific Meeting

June 16 2017

RBP-6000 Investor Event Announcement

June 6 2017

Webcast Event: Shaun Thaxter, CEO of Indivior PLC presented at the Jefferies Global Healthcare Conference on June 6, 2017

May 30 2017

Indivior Submits New Drug Application to U.S. FDA for RBP-6000 Buprenorphine Monthly Depot

May 23 2017

Indivior’s Shaun Thaxter to present at the Jefferies Global Healthcare Conference on June 6th

May 17 2017

2017 Annual General Meeting

March 28 2017

RBP-6000 Phase 3 PK/PD/RO and HEOR Subanalyses

March 23 2017

Annual Report & Accounts 2016 and Annual General Meeting 2017

March 13 2017

Indivior RBP-7000 Top-line results

March 7 2017

Resignation of Cary Clairborne as Chief Financial Officer

March 5 2017

Webcast Event: Q1 2017 Financial Results

March 5 2017

Q1 2017 Indivior Financial Results

March 2 2017

Indivior and Virginia Commonwealth University School of Pharmacy Enter Academic Partnership

February 22 2017

Indivior PLC FY 2016 Financial Results

February 3 2017

Chief Financial Officer Announcement

February 3 2017

Indivior PLC – Appointment of Non-Executive Director

January 11 2017

Shaun Thaxter, CEO of Indivior PLC presented at the JP Morgan Healthcare Conference in San Francisco on January 11, 2017

December 12 2016

Indivior R&D Day

December 9 2016

Indivior PLC Research & Development Day in New York

November 17 2016

Indivior Applauds United States Surgeon General Report

November 2 2016

Nine Month Financial Results: Litigation Provision of $220m Booked: Guidance raised

October 3 2016

Indivior PLC (the “Company”) – Directorate Change

September 27 2016

Statement Regarding Civil Complaint Filed By State Attorneys General

September 23 2016

Indivior Notified of Civil Complaint Filed by State Attorneys General

September 20 2016

INDIVIOR GRANTS $1.2M TO THE MOYER FOUNDATION

September 12 2016

Morgan Stanley Conference, New York 2016 Presentation PDF being used at Morgan Stanley conference on 9/12/2016

August 17 2016

RBP-6000 Phase 3 Top Line Results

July 29 2016

Indivior Half Year 2016 Results

July 29 2016

H1 2016 Indivior Financial Results

July 15 2016

Indivior Announces Intention to List ADRs in U.S.

July 13 2016

Indivior Applauds Congressional Passage of Bipartisan Comprehensive Addiction & Recovery Act of 2016 (CARA)

June 7 2016

Shaun Thaxter, CEO, presented at the Jefferies Healthcare Conference in New York on Tuesday, June 7th, 2016

June 6 2016

Indivior Welcomes Court Ruling on ANDA Litigation

May 26 2016

Indivior Receives FDA Fast Track Designation for RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder

May 11 2016

Indivior Annual General Meeting

May 11 2016

Notice of Annual General Meeting

May 4 2016

Shaun Thaxter, CEO, presented at the Deutsche Bank 41st Annual Health Care Conference in Boston on Wednesday, May 4th.

May 3 2016

INDIVIOR PLC Q1 Financial Results Ahead of Plan. Full Year Guidance Confirmed.

April 28 2016

Result of Phase 1 trial of RBP-6300 Buprenorphine Hemiadipate

April 8 2016

Annual Report & Accounts 2015 and Annual General Meeting 2016

April 7 2016

Indivior PLC (the “Company”) – Directorate Change

February 18 2016

Webcast Event: Indivior Full Year 2015 Results – February 18, 2016

February 18 2016

Presentation: Indivior Full Year 2015 Results

February 18 2016

Indivior Full Year 2015 Financial Results Ahead of Plan. Guidance for 2016 Confirmed.

February 10 2016

Indivior Inc. Receives a Paragraph IV Notice of Certification Letter (‘PIV Notice’) from Teva Pharmaceuticals USA, Inc.

January 14 2016

Shaun Thaxter, CEO of Indivior PLC presented at the JP Morgan Healthcare Conference in San Francisco on January 13, 2016